Racquel D. Innis-Shelton

Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma.

A. Krishnan, R. Vij, P. Hari, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical features

I. Brill, A. Carroll, F. Mikhail, 2015, Cancer Causes & Control.

Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer

L. Bucheit, P. Kasi, J. Starr, 2022, Journal for ImmunoTherapy of Cancer.

Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia

S. Mineishi, L. Lamb, R. Innis-Shelton, 2015, Leukemia & lymphoma.

Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

P. Hari, N. Callander, E. Medvedova, 2019, Blood.